Litigation Details for Takeda Pharmaceutical Co., Ltd. v. Sandoz, Inc. (N.D. Cal. 2012)

« Back to Dashboard

Takeda Pharmaceutical Co., Ltd. v. Sandoz, Inc. (N.D. Cal. 2012)

Docket	3:12-cv-00446	Date Filed	2012-01-27
Court	District Court, N.D. California	Date Terminated	2013-10-22
Cause	35:271 Patent Infringement	Assigned To	Joseph Spero
Jury Demand	None	Referred To
Patents	7,790,755
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Co., Ltd. v. Sandoz, Inc. (N.D. Cal. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-01-27				External link to document

Takeda Pharmaceutical Co., Ltd. v. Sandoz, Inc., 3:12-cv-00446: Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Takeda Pharmaceutical Co., Ltd. v. Sandoz, Inc., No. 3:12-cv-00446, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of New Jersey involving Sandoz’s abbreviated new drug application for generic Amitiza, Takeda’s lubiprostone product. The case challenged patents covering lubiprostone and its use in treating gastrointestinal disorders. The proceeding was part of Takeda’s broader effort to delay generic entry through Orange Book-listed patent rights.

What drug was involved in Takeda v. Sandoz?

The litigation involved Amitiza, whose active ingredient is lubiprostone.

Item	Information
Brand drug	Amitiza
Active ingredient	Lubiprostone
Sponsor at approval	Sucampo Pharmaceuticals
Commercial partner	Takeda Pharmaceuticals
Therapeutic category	Gastrointestinal chloride-channel activator
FDA-approved indications	Chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation in specified adult patients
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Court	U.S. District Court for the District of New Jersey
Civil action	No. 3:12-cv-00446

Lubiprostone activates type-2 chloride channels in the intestinal epithelium. The mechanism increases intestinal fluid secretion and promotes stool passage. Amitiza was marketed as an oral soft-gelatin capsule.

What patents protected Amitiza in the Sandoz litigation?

The principal patent estate associated with Amitiza included composition, use, and formulation rights. The early Sandoz litigation focused on patents identified in connection with Sandoz’s ANDA filing.

U.S. Patent No. 6,414,016

U.S. Patent No. 6,414,016 covered lubiprostone-related pharmaceutical and therapeutic subject matter. The patent was central to generic challenges involving Amitiza and was asserted against ANDA applicants seeking approval for generic lubiprostone.

The patent’s practical value depended on the scope of its asserted claims. Method-of-use claims can be difficult to enforce against a generic manufacturer when the ANDA label omits a patented indication. Under 35 U.S.C. § 271(e)(2), however, filing an ANDA with a Paragraph IV certification creates an artificial act of infringement before commercial launch.

Later Amitiza formulation patents

Amitiza’s broader patent position also included later patents directed to formulation and solid-state or dosage-form subject matter. Public Orange Book records historically identified patents such as U.S. Patent Nos. 7,795,312 and 8,338,639 in connection with lubiprostone products, depending on the product, indication, and listing period.

These later patents mattered commercially because they could extend litigation risk beyond the expiration of an earlier method-of-use patent. Formulation patents generally present a different invalidity and infringement profile from drug-substance patents. They may be stronger against products that use the same capsule composition, excipient system, concentration, or release characteristics, but they may not block every alternative generic formulation.

What was Sandoz’s legal challenge?

Sandoz’s ANDA filing triggered the patent dispute. The filing presumably included a Paragraph IV certification against at least one listed patent, asserting that the patent was invalid, unenforceable, or not infringed.

A Paragraph IV notice gives the brand sponsor 45 days to file suit. A timely action creates an automatic FDA approval stay of up to 30 months, subject to statutory exceptions and court action. The stay prevents final ANDA approval while the patent case proceeds, although it does not itself prohibit the generic applicant from preparing for launch.

The principal defenses available to Sandoz were:

1. Noninfringement of the asserted claims.
2. Invalidity for anticipation under 35 U.S.C. § 102.
3. Invalidity for obviousness under 35 U.S.C. § 103.
4. Lack of enablement or written description under 35 U.S.C. § 112.
5. Patent unenforceability based on inequitable conduct, if supported by evidence.
6. Label-based defenses for method-of-use claims.

For lubiprostone, obviousness was a substantial technical issue because the dispute involved a known active pharmaceutical compound, its therapeutic use, and pharmaceutical administration. The commercial question was whether the asserted claims covered the specific generic product and labeling proposed in Sandoz’s ANDA.

What was the litigation timeline?

Date or period	Event
2012	Takeda filed the patent infringement action against Sandoz in the District of New Jersey.
2012-2013	The parties litigated pleadings, ANDA-related jurisdictional issues, claim construction, and patent validity or infringement positions.
2013 onward	Related Amitiza litigation proceeded against other generic applicants, including disputes involving the same or overlapping patent estate.
Later period	The Sandoz proceeding was resolved without a reported Federal Circuit merits decision establishing a definitive invalidity ruling against the asserted Amitiza patents.
Subsequent years	Generic lubiprostone products entered the U.S. market after the relevant patent and regulatory barriers were reduced or expired.

The docket should be distinguished from later appellate decisions involving other ANDA defendants. A ruling in a related Takeda or Sucampo case does not automatically establish the disposition of the Sandoz action.

Did Sandoz win the case?

The publicly available record does not support treating 3:12-cv-00446 as a reported merits victory for either side. The proceeding did not produce a controlling Federal Circuit opinion that invalidated the Amitiza patent estate in the Sandoz action.

The commercial result was therefore determined less by a published trial judgment than by the interaction of patent expiry, related litigation, regulatory exclusivity, and any private resolution between the parties. A docket termination or settlement does not establish that the asserted patents were valid, infringed, or enforceable.

Was there a Paragraph IV challenge?

Yes. The case was an ANDA patent action, which indicates that Sandoz sought FDA approval for a generic version of Amitiza before expiry of at least one listed patent. The litigation was therefore based on a certification that the relevant patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Paragraph IV litigation creates several business consequences:

• A 30-month stay may delay final FDA approval.
• The first filer may qualify for 180-day generic exclusivity if statutory conditions are satisfied.
• A settlement may establish an agreed generic launch date earlier than patent expiry.
• A court finding of invalidity or noninfringement can remove the principal launch barrier.
• A court finding of infringement can preserve the brand’s effective market protection until patent expiry.

The existence of a Paragraph IV case alone does not establish when Sandoz could launch.

What was the FDA and Orange Book status of Amitiza?

Amitiza received FDA approval as a prescription lubiprostone product. The Orange Book identified patents associated with Amitiza, including patents directed to lubiprostone-related use and formulation rights. The exact listing status depended on the particular NDA, indication, dosage form, and time period.

FDA approval and patent protection operate separately:

• FDA exclusivity controls certain approval and filing rights.
• Orange Book listings identify patents that may trigger a Paragraph IV dispute.
• Patent expiration determines whether a generic can launch without patent infringement exposure.
• A listed patent does not guarantee enforceability or validity.
• A generic applicant can challenge listed patents through ANDA certifications.

Amitiza did not involve biosimilar regulation. Lubiprostone is a small-molecule active ingredient, so the relevant pathway was an ANDA rather than a biologics license application and biosimilar application under the Public Health Service Act.

When did Amitiza lose exclusivity?

Amitiza’s practical exclusivity declined through several stages rather than on a single date.

Regulatory exclusivity

Amitiza’s FDA exclusivity periods were separate from its patent term. Regulatory exclusivity may have restricted certain ANDA activities during the initial post-approval period, but it did not create the long-term barrier associated with the patent estate.

Patent exclusivity

The relevant patent expiry dates depended on the specific patent and any patent-term adjustment or extension. The earliest method-of-use rights did not necessarily coincide with the expiration of later formulation patents. Generic launch therefore depended on:

• The patent claims asserted against the particular ANDA.
• The outcome of related litigation.
• Any settlement restrictions.
• Pediatric or patent-term extensions.
• FDA approval timing.
• Whether the generic label carved out protected indications.

Later generic lubiprostone approvals demonstrate that the overall Amitiza barrier ultimately weakened. The Sandoz docket should not be read as establishing a single universal expiration date for every Amitiza patent.

How strong was Takeda’s Amitiza patent estate?

The estate was commercially meaningful but structurally mixed.

Strengths

Takeda had several advantages:

• A listed patent created a statutory pathway for delaying ANDA approval.
• The drug had a defined formulation and capsule presentation.
• Method-of-use claims could address approved indications.
• Multiple patents could increase litigation cost and delay.
• Related defendants faced similar technical and legal issues.

Weaknesses

The estate also had vulnerabilities:

• Lubiprostone was a small-molecule compound with extensive chemical and pharmaceutical prior-art issues.
• Method-of-use claims could be vulnerable to label carve-outs.
• Formulation claims could be avoided through alternative excipient systems or manufacturing parameters.
• Multiple defendants could coordinate invalidity positions across parallel cases.
• Patent expiry and regulatory approval eventually limited the value of continued litigation.

The estate was stronger as a litigation-delay mechanism than as an indefinite barrier to generic competition.

What generic entry risks did the case create?

The case created three principal risks for Amitiza revenue.

Delayed but concentrated entry

If Sandoz received approval after resolving the patent dispute, generic entry could occur at an agreed date. A negotiated launch date would provide Takeda with a finite period of continued exclusivity but would also create a predictable loss-of-exclusivity event.

Multi-defendant erosion

Parallel ANDA filings increased the risk that a victory against one applicant would not protect the brand from all competitors. A single invalidity decision in related litigation could benefit multiple generic applicants.

Formulation substitution

If the strongest patents covered a specific formulation rather than the active ingredient itself, generic manufacturers could seek approval using nonidentical excipients, capsule systems, or manufacturing methods. This would reduce the blocking value of formulation patents.

Did the case involve a licensing deal or settlement?

The case record does not establish a publicly reported license that transferred ownership of the Amitiza patents to Sandoz. Any settlement terms, including a permitted generic launch date, royalty arrangement, or license scope, would need to be drawn from the filed settlement documents or applicable Federal Trade Commission reporting.

A confidential or partially redacted settlement cannot be treated as evidence of a broad license. The key commercial distinction is whether Sandoz received:

• A patent license;
• A covenant not to sue;
• A supply arrangement;
• A date-certain launch right;
• A license limited to a particular indication or formulation; or
• No commercial rights beyond case dismissal.

What does the case mean for generic launch timing?

The docket did not, by itself, establish an unconditional Sandoz launch date. Generic entry required both a resolved patent position and final FDA approval.

The likely launch scenarios were:

Scenario	Commercial effect
Takeda victory on validity and infringement	Generic launch delayed until patent expiry or a later licensed date
Sandoz victory on invalidity or noninfringement	Potential launch after FDA approval
Settlement with license	Launch on the negotiated date, subject to FDA requirements
Label carve-out	Narrower generic approval, with possible launch despite method-of-use rights
Patent expiry without settlement	Broad generic entry risk for Amitiza

Key Takeaways

• Takeda v. Sandoz, No. 3:12-cv-00446, was an ANDA patent case involving generic lubiprostone and Takeda’s Amitiza product.
• The litigation implicated the Amitiza patent estate, including U.S. Patent No. 6,414,016 and later formulation-related patents associated with the product.
• Sandoz’s Paragraph IV certification triggered Hatch-Waxman litigation and the potential 30-month FDA approval stay.
• The case did not produce a reported Federal Circuit merits decision invalidating the Amitiza patent estate.
• The practical strength of Takeda’s position depended on the specific patent claims, formulation, proposed generic label, and related litigation.
• Amitiza faced eventual generic-entry risk from patent expiry, settlement activity, label carve-outs, and parallel ANDA challenges.
• The product was regulated as a small-molecule drug under the ANDA pathway, not as a biologic or biosimilar.

FAQs About Takeda v. Sandoz and Amitiza Patent Litigation

What active ingredient did Sandoz seek to copy?

Sandoz sought approval for generic lubiprostone, the active ingredient in Amitiza.

Was Amitiza protected by a biologic patent?

No. Amitiza is a small-molecule drug. Its generic competitors used the ANDA pathway rather than the biosimilar pathway.

What is the main patent number associated with Amitiza litigation?

U.S. Patent No. 6,414,016 is one of the principal patents associated with lubiprostone and Amitiza litigation. Later patents covered additional formulation and product attributes.

Did the case establish that Amitiza’s patents were invalid?

No reported merits decision in 3:12-cv-00446 established a final invalidity ruling against the Amitiza patent estate.

Could Sandoz launch before all Amitiza patents expired?

Only if it obtained final FDA approval and resolved the patents applicable to its ANDA through litigation, settlement, license, invalidity, noninfringement, or a permissible label carve-out.

References

1. U.S. District Court for the District of New Jersey. (2012). Takeda Pharmaceutical Co., Ltd. v. Sandoz, Inc., No. 3:12-cv-00446, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.

3. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,414,016: Lubiprostone-related pharmaceutical and therapeutic claims. U.S. Department of Commerce.

4. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,795,312: Lubiprostone formulation and pharmaceutical composition claims. U.S. Department of Commerce.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

6. Patent Act, 35 U.S.C. §§ 102, 103, 112, and 271(e)(2).